Physician profile
Sujata Reddy
NPI 1912122581
$1,554.20
in general payments reported to CMS, 2019-2025
31 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $177 · 2021: $404 · 2022: $39.75 · 2023: $230 · 2024: $166 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $240.12 | 2019-2021 | |
| Amgen INC. | $167.89 | 2019-2024 | Repatha |
| Sirtex Medical INC | $128.01 | 2023 | Sir-Spheres Microspheres |
| Astrazeneca Pharmaceuticals LP | $89.37 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $87.18 | 2019-2024 | Spravato |
| Novo Nordisk INC | $73.32 | 2019-2021 | |
| Lilly USA, LLC | $60.78 | 2019-2021 | |
| Amarin Pharma, INC. | $58.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $57.37 | 2019-2021 | |
| Eisai INC. | $55.37 | 2021 | |
| Pfizer INC. | $54.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.36 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $43.67 | 2021 | |
| Irhythm Technologies, INC. | $39.75 | 2022 | |
| Glaxosmithkline, LLC. | $36.53 | 2024 | Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $35.20 | 2023 | Symtuza |
| Travere Therapeutics, INC. | $34.90 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.02 | 2025 | |
| Ironwood Pharmaceuticals, INC | $28.72 | 2021-2024 | |
| Axsome Therapeutics, INC. | $22.20 | 2025 | Auvelity |
| Abbvie INC. | $21.36 | 2021 | |
| Apellis Pharmaceuticals, INC. | $17.82 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $16.88 | 2021 | |
| Allergan, INC. | $14.92 | 2020 | |
| Akebia Therapeutics INC | $14.21 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.83 | 2021 | |
| Nxstage Medical, INC. | $13.48 | 2023 | Nxstage System One |
| Phathom Pharmaceuticals, INC. | $13.02 | 2025 | Voquezna |
| Gilead Sciences, INC. | $12.67 | 2020 | |
| Mannkind Corporation | $12.34 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujata Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.